Loading...
NPI 1720409154 · Indianapolis, IN · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Patients Choice Laboratories Of Indiana, LLC is a clinical medical laboratory provider located in Indianapolis, Indiana. This profile covers 117 Medicare and 148 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Patients Choice Laboratories Of Indiana, LLC |
| Address | 7026 Corporate Dr |
| City | Indianapolis |
| State | IN |
| ZIP | 46278 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | January 3, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $23.4M |
| Medicare | $17.3M |
PATIENTS CHOICE LABORATORIES OF INDIANA, LLC is a high-volume clinical molecular and toxicology laboratory: its top Medicare revenue drivers are molecular amplified-probe tests (87798 and 87150) and definitive multi-class drug testing (G0483), and the detailed code mix includes many amplified nucleic acid probe assays (e.g., 87481, 87640, 87653) plus pharmacogenomic testing (81418), consistent with a lab focused on nucleic-acid infectious disease panels and centralized definitive drug testing services. The presence of comprehensive panels (G0483, G0482, G0481) alongside many organism-specific amplified probe codes indicates operations that combine high-throughput molecular diagnostics with confirmatory toxicology workflows.
Revenue is highly concentrated on a small set of Medicare codes: the precomputed top-3 Medicare codes account for 76.6% of total Medicare revenue, with 87798 alone contributing $6M (35.7% of Medicare revenue) and 87150 contributing $4.7M (28.3%). This concentration suggests the provider’s Medicare business depends heavily on a few high-volume molecular and confirmatory drug-testing services rather than a broad diversity of low-revenue panels.
On the Medicaid side the provider is even more concentrated: G0483 generates $9.2M, representing 41.9% of its total Medicaid revenue, and the precomputed top-3 Medicaid codes account for 61.6% of total Medicaid revenue. Medicaid income is therefore dominated by definitive multi-class drug testing and a handful of amplified-probe infectious disease assays (87798, 87150), indicating similar service focus across both payers but with larger absolute Medicaid revenue ($23.4M) than Medicare ($17.3M).
The provider is a market leader on many of its highest-volume codes: for Medicare, 87150 ranks #1 nationally of 190 providers (100th percentile) and 87798 ranks #5 of 1319 providers (100th percentile), both labeled as “extreme outlier” volumes compared with national peers. For Medicaid in Indiana, this lab ranks #1 of peers on multiple high-revenue codes (G0483, 87798, 87150, U0003, and several others), often at the 100th percentile, indicating dominant in-state positioning for both definitive drug testing and amplified-probe molecular assays.
Medicaid exceeds Medicare in lifetime revenue for this entity: lifetime totals show $23.4M from Medicaid vs. $17.3M from Medicare, so the lab’s payer mix skews toward Medicaid while maintaining substantial Medicare activity. The parallel code mix across payers implies the lab serves both populations with the same core services rather than operating distinct lines for each payer.
Many individual codes are labeled statistical outliers or notably above typical volume, which reinforces the provider’s role as a high-throughput specialty lab rather than a general hospital laboratory. Examples include G0483 (Medicare rank #9 nationally, 99th percentile; Medicaid rank #1 in-state, 100th percentile, labeled extreme outlier), 87150 (Medicare rank #1 nationally, 100th percentile; Medicaid rank #1 in-state, 100th percentile), and multiple amplified-probe organism tests (e.g., 87641, 87653, 87500) with 99–100th percentile standings.
Operational tenure is long enough to establish market presence: the NPI was enumerated on 2014-01-03 (~12 years ago), suggesting the lab has had over a decade to scale high-volume testing workflows and referral networks that would support the observed extreme volumes on selected codes. That tenure supports the durability of its service specialization in molecular diagnostics and definitive toxicology.
The provider’s revenue profile implies business risk from concentration: because top-3 Medicare codes drive 76.6% of Medicare revenue and top-3 Medicaid codes drive 61.6% of Medicaid revenue, reimbursement changes, coding policy updates, or payor-level contract shifts affecting those specific molecular or drug-testing codes could materially impact overall revenue. The heavy reliance on a few high-volume assay types warrants attention from payer analysts when evaluating contracting or utilization-management interventions.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
117 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 175,280 | $30 | $6M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 139,260 | $30 | $4.7M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 8,700 | $240 | $2.1M |
| 87481 | The lab analyst performs a test for Candida species using amplified nucleic acid probe technique. | 25,270 | $20 | $556K |
| 87640 | The lab analyst performs the technical lab test to look for Staphylococcus aureus nucleic acid using an amplified probe technique. | 13,480 | $30 | $458.4K |
| 87653 | The lab analyst performs a test for Streptococcus, group B, using amplified nucleic acid probe technique. The amplified probe provides a rapid means to assess colonization by Streptococcus, group B,… | 12,990 | $30 | $441.6K |
| 87500 | The lab analyst performs a test for vancomycin resistance in an infectious organism’s nucleic acid using amplified probe technique. VRE, vancomycin resistant enterococcus, is the most common organism… | 12,720 | $30 | $432.5K |
| 87641 | The lab analyst performs a test for methicillin–resistant Staphylococcus aureus (MRSA) using an amplified nucleic acid probe technique. | 12,610 | $30 | $428.9K |
| 81418 | Code 81418 describes a test to evaluate a blood or saliva specimen for changes in at least six genes that may impact metabolism of many therapeutic drugs. The test must include CYP2C19 and CYP2D6… | 400 | $890 | $359.9K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,560 | $200 | $303.6K |
Showing 1–10 of 117
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 117 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
148 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 126,400 | $70 | $9.2M |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 40,740 | $60 | $2.6M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 42,420 | $40 | $1.7M |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 32,680 | $50 | $1.7M |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 61,940 | $30 | $1.5M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 49,600 | $20 | $1M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 15,890 | $40 | $683.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 29,620 | $20 | $621.9K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 38,460 | $10 | $307.7K |
| 87502 | The lab analyst performs a test to determine the presence of multiple types or subtypes of influenza virus through nucleic acid detection using multiplex amplified probe technique and possibly… | 11,590 | $30 | $301.4K |
Showing 1–10 of 148
How this provider's Medicaid billing volume and revenue compare to other Indiana providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Indiana median
148 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 20 | 1,610 | $70 | $841.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 30 | 400 | $90 | $443.4K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 5 | 190 | 800 | $40 | $344.7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 90 | 1,150 | $60 | $289.6K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 20 | 1,160 | $50 | $236.5K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 1 | 40 | 160 | $80 | $173.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 90 | 390 | $40 | $171.1K |
| 87150 | The lab analyst performs an analysis using amplified DNA or RNA probe technique on a previously isolated and identified organism to categorize the organism more specifically, such as to the taxonomic… | 1 | 10 | 70 | $50 | $145.9K |
| 80050 | The lab analyst performs testing for the specific group of clinical laboratory procedures in the general health panel. Payers typically consider 80050 to apply only when the clinician orders the… | 56 | 80 | 340 | $70 | $139.8K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by… | 10 | 30 | 670 | $60 | $130.6K |
Showing 1–10 of 148
Other providers in the same ZIP code as Patients Choice Laboratories Of Indiana, LLC, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| American Health Network Of Indiana, LLC | IN | Internal Medicine Physician | $0 | $15.3M |
| Kci Usa Inc. | IN | Durable Medical Equipment & Medical Supplies | $0 | $10.1M |
| Landmark Recovery Of Carmel LLC | IN | Substance Abuse Rehabilitation Facility | $0 | $6.4M |
| Pharmaneek Inc | IN | Pharmacy | $6.2M | $17.8K |
| Aria Diagnostics LLC | IN | Clinical Medical Laboratory | $647.7K | $3.9M |
| Kacy Rogers | IN | Nurse Practitioner | $643.1K | $0 |
| Brian Wiegel | IN | Diagnostic Radiology Physician | $446.5K | $0 |
| Timothy Davis | IN | Diagnostic Radiology Physician | $429.5K | $0 |
| Florentino Ferrer | IN | Physical Therapist | $244.3K | $0 |
| Michael Conley | IN | Diagnostic Radiology Physician | $231.2K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.